Last reviewed · How we verify
NCT06680180: FORTITUDE
Fibrinolysis Resistance in Infection and Trauma
trial testing Viscoelastometric assessment of fibrinolysis in Sepsis and Septic Shock in 150 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Anders Aneman |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 June 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 1 June 2026 |
| Sites | 4 locations across Australia |
Drugs / interventions tested
- Viscoelastometric assessment of fibrinolysis
Conditions studied
- Sepsis and Septic Shock — all drugs for Sepsis and Septic Shock →
- Trauma — all drugs for Trauma →
Sponsor
Anders Aneman
Who can join
18 and older, any sex, with Sepsis and Septic Shock or Trauma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Blood coagulation disorders are often seen in critically ill patients e.g. with severe infection or following extensive injury, that can lead to life threatening events as a result of excessive blood clot formation leading to organ failure. This study aims to use Viscoelastic Testing (VET) technology to detect patients at risk of excessive blood blot formation at the bedside, test new blood coagulation drugs, and guide life-saving use of blood modifying treatments.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06680180
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sepsis and Septic Shock
Currently open trials in the same condition.
- NCT06809868 — Role of Transposable Elements in Septic Immune Aging · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06680180 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anders Aneman
- Last refreshed: 8 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06680180.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing